Business
Grass MATA MPL dossier submitted in Switzerland
Grass MATA MPL dossier submitted in Switzerland.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 4623E Allergy Therapeutics PLC 07 April 2011 \n \n\n7 April 2011\n \nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or \"the Company\")\n \nAllergy submits Grass MATA MPL dossier in Switzerland\n \nAllergy Therapeutics PLC (AGY), the specialist pharmaceutical company focused on allergy vaccination, is pleased to announce that it has submitted a Marketing Authorisation Application ('MAA') for Grass MATA MPL (a new formulation of Pollinex® Quattro) in Switzerland. \n \nThe MAA has been submitted to the Swiss regulatory authority, Swissmedic, and, on approval, the product will be distributed by Swiss-based Teomed AG, acquired by the Company in 2010. The Swiss allergy vaccine market is estimated to be worth between £8-10 million.\n \nThe Company's flagship product, Pollinex Quattro, is sold across Europe on a named patient basis and consists of just 4 injections over 3 weeks, offering sufferers a safe and effective therapy with a much more convenient treatment regime than is currently available.\n \nManuel Llobet, Chief Executive of Allergy Therapeutics, said:\n\"This is our 12th MAA submission in 2 years and marks another strategic milestone for the Company as not only does it represent the first submission of the Grass MATA MPL MAA outside the EU, it also leverages the distribution capabilities of Teomed AG, our Swiss-based distributor, acquired by the Company in 2010.\"\n \n \nFor further information\n \n\n\n\n\nAllergy Therapeutics\n\n\n+44 (0) 1903 845 820\n\n\n\n\nManuel Llobet, Chief Executive Officer\n\n\n\n\n\n\n\nIan Postlethwaite, Finance Director\n\n\n\n\n\n\n\nwww.allergytherapeutics.com\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNomura Code Securities\n\n\n+44 (0) 207 776 1200\n\n\n\n\nJuliet Thompson/ Clare Terlouw\n\n\n\n\n\n\n\nwww.nomuracode.com\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFinancial Dynamics\n\n\n+44 (0) 207 831 3113\n\n\n\n\nBen Brewerton/ Susan Quigley\n\n\n\n\n\n\n\n \n \nAbout Allergy Therapeutics \n \nAllergy Therapeutics plc is a London Stock Exchange (AIM) listed, integrated specialist pharmaceutical company focused on allergy vaccination. It has a growing, profitable business achieving sales of allergy vaccines of £41 million mainly in Europe through its own sales and marketing infrastructure and further afield through dis...